Wefunder logo

InvVax

We use a new genetics platform to develop better vaccines for flu, COVID-19, etc

Last Funded April 2024

$124,203

raised from 132 investors

Highlights

1
Huge global market for these vaccines: Universal flu - $22B; COVID-19 - $5B
2
Chance to make an enormous societal impact
3
Patented durable and universal flu vaccine
4
Major smashes: Moderna, BioNTech, Novavax: Invest in the next one!

Featured Investor

Invested $2,500

“InvVax is fundamentally changing the way in which antiviral vaccines are developed. Leveraging years of technical and commercial experience in the space, the InvVax team has developed a breakthrough platform that significantly increases the vaccine hit rate against current, emerging and future variants of viruses such as Influenza, Hepatitis and SARS-COV-2. InvVax is collaborating with leading global researchers in the space to apply their best knowledge and move the technology to the next ...”

Our Team

CEO
PhD from a top 5-medical school; Postdocs at Harvard and UCLA; Pioneered a powerful new viral genetics platform applicable to vaccines and therapies
Nima ShivaHead of Business Development
Managing Director, Convergent Ventures; Founder, Encode Bio; Co-founder, Neurion Pharmaceuticals
Olga PetrauskeneDirector
COO, Diagnosticcs Biosystems; Produced an HIV and flu diagnostic with Applied Biosystems that is sold in 60 countries

*To our knowledge, this is the only universal flu vaccine targeting invariant sequence of influenza, but there could be, in theory, others that we do not know about.

Source: Vision Research Reports.

To our knowledge, we are the only company focused on invariance. There could be others we do not know about.

Forward-looking projections are not guaranteed.

Forward-looking projections are not guaranteed.

Overview